This study assessed the absolute and relative bioavailabilities of dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides (tetraene), one of the main bioactive constituents in Echinacea, administered as pure compounds or as an Echinacea purpurea root extract preparation. Ten rats received 0.75 mg/kg dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides oral, pure and within 158.6 mg/kg Echinacea purpurea extract, or intravenous. Pharmacokinetic parameters and bioavailability data of tetraene were obtained by noncompartmental analysis using WinNonlin ® 5.2 software. Mean dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamide plasma area under the concentration-time curve (AUC 0-∞ /Dose) was 3.2 ± 0.3 min*ng/mL/µg and 1.0 ± 0.2 min*ng/mL/µg after iv and oral administration, respectively, and 1.5 ± 0.2 min*ng/mL/µg after oral administration of the Echinacea root extract. The absolute and relative bioavailability of dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides were 29 % and 47 %, respectively. Administration of a whole Echinacea extract increases blood exposure with no impact on C max . The high area under the curve concentration resulted in a longer elimination half-life with 123 min in comparison to 36 min after administration of the pure dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides. A rapid absorption followed by a slower elimination phase was observed.
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